Author: Marsh, Glenn A.; McAuley, Alexander J.; Au, Gough G.; Riddell, Sarah; Layton, Daniel; Singanallur, Nagendrakumar B.; Layton, Rachel; Payne, Jean; Durr, Peter A.; Bender, Hannah; Barr, Jennifer A.; Bingham, John; Boyd, Victoria; Brown, Sheree; Bruce, Matthew P.; Burkett, Kathie; Eastwood, Teresa; Edwards, Sarah; Gough, Tamara; Halpin, Kim; Harper, Jenni; Holmes, Clare; Horman, William S. J.; van Vuren, Petrus Jansen; Lowther, Suzanne; Maynard, Kate; McAuley, Kristen D.; Neave, Matthew J.; Poole, Timothy; Rootes, Christina; Rowe, Brenton; Soldani, Elisha; Stevens, Vittoria; Stewart, Cameron R.; Suen, Willy W.; Tachedjian, Mary; Todd, Shawn; Trinidad, Lee; Walter, Duane; Watson, Naomi; Drew, Trevor W.; Gilbert, Sarah C.; Lambe, Teresa; Vasan, S. S.
Title: ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets Cord-id: 9rfjp79b Document date: 2021_5_10
ID: 9rfjp79b
Snippet: Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trials, the efficacy of ChAdOx1 nCoV-19 against SARS-CoV-2 challenge was evaluated in a ferret model of infection. Groups of ferrets received either prime-only or prime-boost administration of ChAdOx1 nCoV-19 via t
Document: Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trials, the efficacy of ChAdOx1 nCoV-19 against SARS-CoV-2 challenge was evaluated in a ferret model of infection. Groups of ferrets received either prime-only or prime-boost administration of ChAdOx1 nCoV-19 via the intramuscular or intranasal route. All ChAdOx1 nCoV-19 administration combinations resulted in significant reductions in viral loads in nasal-wash and oral swab samples. No vaccine-associated adverse events were observed associated with the ChAdOx1 nCoV-19 candidate, with the data from this study suggesting it could be an effective and safe vaccine against COVID-19. Our study also indicates the potential for intranasal administration as a way to further improve the efficacy of this leading vaccine candidate.
Search related documents:
Co phrase search for related documents- acceptable safety profile and adenovirus vaccine: 1
- acute respiratory syndrome and addition medium: 1, 2, 3, 4, 5, 6, 7
- acute respiratory syndrome and additional animal: 1, 2, 3
- acute respiratory syndrome and adenovirus vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and adenovirus vaccine platform: 1
- acute respiratory syndrome and administration regimen: 1, 2, 3, 4
- acute respiratory syndrome and administration route: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and low respiratory tract: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute respiratory syndrome and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and macaque model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- additional animal and adenovirus vaccine: 1
- adenovirus vaccine and administration route: 1
- adenovirus vaccine and macaque model: 1
- adenovirus vaccine platform and administration route: 1
- adenovirus vaccine platform and macaque model: 1
- administration regimen and lymph node: 1
- administration route and low respiratory tract: 1
- administration route and lymph node: 1
- administration route and macaque model: 1
Co phrase search for related documents, hyperlinks ordered by date